CliffBio
small molecule

MYTESI

CROFELEMER

Loss of exclusivityOctober 2031latest FDA-listed patent expiry
CompanyNapo Pharmaceuticals, Inc. →View the full company profile on CliffBio

Drug detail

Brand nameMYTESI
Active ingredientCROFELEMER
Strength125MG
Dosage formTABLET, DELAYED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2012
Marketing statusRX

Listed patents

PatentExpiresType
9585868October 2031use U-1319
8962680October 2031use U-1319

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

MYTESI patent cliff — loss of exclusivity October 2031 | CliffBio